CLEARER JOURNAL · OCULAR LONGEVITY
By Clearer Research
24 July 2026 · 5 min read
Earlier this week, the longevity influencer Bryan Johnson, famed for spending $2 million a year on biohacking and health protocols and starting the ‘Don’t Die’ movement, wrote on X: ‘Eye health has been absent from longevity and health discussions. Is this accurate or have I just missed it?’ He then added, ‘I know people speak to diet and supplements for eye health. I’m referring to robust measurement, diagnosis of dysfunction and robust protocols to correct.’
It is an excellent question. As an organ, the eye is particularly prone to ageing because it’s highly metabolically active and constantly exposed to optical stressors. As Professor Glen Jeffery states, ‘the retina ages faster than any other organ.’ Very importantly, some critical tissues within the eye cannot regenerate, so once damage occurs, it is often irreversible. Vision decline not only leads to the loss of sight but also negatively affects other parts of health and lifestyle, including cognition and movement.
However, among longevity advocates, eye health is eclipsed by other areas of health. Longevity enthusiasts measure glucose by the minute, sleep by the night, and cardiovascular fitness across the year; they track bone density, lean mass, lipids, hormones, cognition, and epigenetic age. At the same time, very few could name a single measurement that tells them how their retina, optic nerve, lens or the clear gel filling most of the eye is changing over time.
What is missing from the current approach to eye care? What would ocular longevity entail? In this newsletter, we focus on the difference between medical and longevity approaches to vision health, the issues of measurement and diagnosis, and how vitreous health reveals the shortcomings of standard clinical practice. In our future newsletters, we will discuss the latest longevity strategies for vision health.
01 · THE MISSING PIECE
Ophthalmology has spent generations studying cataracts, glaucoma, retinal degeneration and other conditions associated with ageing, and it owns some of the most precise imaging technologies in medicine, such as Optical Coherence Tomography (OCT).
However, conventional eye care is built around a familiar clinical question: is there a recognised condition that requires monitoring or treatment? The focus is on eye diseases. However, the important thing about vision decline is that when diseases become clinically apparent, irreversible damage has already occured within the eye as a result of long-term degeneration.
Longevity medicine asks something different: how quickly is this apparently healthy organ changing, and can its trajectory be improved before disease appears? When it comes to measurement and diagnosis, conventional examination asks: Is there glaucoma? Is the retina attached? Is the macula structurally normal? Does the prescription need changing? Has a finding crossed the threshold for treatment?
Longevity medicine asks something different: how quickly is this apparently healthy organ changing, and can its trajectory be improved before disease appears?
When it comes to measurement and diagnosis, conventional examination asks:
Is there glaucoma?
Is the retina attached?
Is the macula structurally normal?
Does the prescription need changing?
Has a finding crossed the threshold for treatment?
A longevity-oriented assessment would add:
Is the optic nerve changing faster than expected?
Is visual performance declining before letter-chart acuity changes?
How does this person compare with their own baseline rather than the population average?
Are changes in retinal circulation related to their metabolic or vascular health?
Which measurements are modifiable, and which are merely interesting?
02 · MEASUREMENT
A routine eye test with an optometrist includes visual acuity, refraction, intraocular pressure, and a few other core metrics. However, it may not examine or quantify subtle structural or functional changes within the eye. A more advanced and comprehensive eye exam at an eye clinic or with an ophthamologist would include visual field tests, colour fundus photography, OCT, and specialist assessments for dry eye and corneal conditions.
Bryan Johnson asks about ‘robust measurement and diagnosis of dysfunction’, so what does the frontier of vision assessment look like?
One area is cellular imaging, which allows examination of not only retinal layers, as the standard OCT does, but also individual cells within the retina. Experimental functional imaging is also beginning to measure how those cells respond to light.
Another important area of research is oculomics, the attempt to derive signals about systemic health from retinal imaging, which is the only place where blood vessels and nerve tissue can be photographed directly and non-invasively in seconds. Models trained on retinal photographs can already estimate a person's age, sex, smoking status and blood pressure, and in a UK Biobank analysis of around 36,000 people, a retina that looked older than its owner was associated with a higher risk of death during follow-up.
Another interesting development involves biomarkers from tear fluid. A few microlitres of tears, collected on a paper strip in under a minute, contain more than a thousand identifiable proteins. Tear proteomics and metabolomics are now being used to hunt for signatures of dry eye, diabetic retinopathy, glaucoma and conditions well beyond the eye.
These frontier applications remain at the research stage or confined to specialist centres and have not yet become standard preventive care.
03 · VITREOUS HEALTH
As our customers know well, the vitreous is the transparent gel filling the large space between the lens and the retina, and its structure depends on an extremely fine network of collagen, hyaluronan and water. It does not stay that way for life. As the vitreous ages, parts of the gel liquefy, and collagen fibres can become less evenly organised. Those structures scatter light and cast moving shadows on the retina: the dots, threads, cobwebs and translucent shapes that becomes eye floaters. In time the vitreous may also separate from the retina altogether, causing a posterior vitreous detachment, or PVD.
The clinical conversation then follows a familiar pattern. When new floaters or flashes appear, the urgent priority is ruling out retinal emergencies: examine the peripheral retina and rule out a tear or a detachment. If the retina is intact and central acuity is good, the usual recommendation is observation. Many people adapt, and invasive treatments such as vitrectomy would expose a generally healthy eye to risks that can outweigh the benefit. That logic is medically defensible.
However, it also shows the limits of a reactive model. Once the retina is judged safe, the conversation goes like this: eye floaters are common, try to ignore them, come back if they suddenly get worse. The vitreous becomes clinically interesting when it pulls on the retina, creates a tear, causes a macular complication, or disturbs vision enough to justify surgery. The decades of structural change before that point are rarely explained as part of ageing, rarely measured, and rarely connected to any broader conversation about long-term and systemic health. For patients, ‘not dangerous’ can easily sound like ‘not meaningful’.
Yet, floaters can interfere with contrast sensitivity, reading, screen work, driving and quality of life while standard acuity stays good. For that reason, some vitreous specialists propose to reframe eye floaters as ‘Vision-Degrading Myodesopsia’ to highlight its negative impacts on visual function.
Meanwhile, the vitreous is not biologically separate from the rest of the body. Its collagen-and-hyaluronan structure exists within the same metabolic environment as every other tissue, and over time it is exposed to oxidative stress, glycation and changes in connective-tissue integrity. Age is the main driver, while high myopia, diabetes, and some inherited connective-tissue disorders can alter the context or timing of vitreous change. Nutrition, smoking, metabolic health, and environmental exposure also influence the broader biological environment of the eye, including the vitreous.
When opticians say 'eye floaters are normal and there is nothing to be done', the response elides the complexity of vitreous biology and proactive strategies for understanding symptoms, managing modifiable risk, monitoring change, and supporting overall eye health.
Over the past few years, at Clearer Eyecare, we have focussed on vitreous health and nutraceutical appraoches to preventative eye care. Based on the only existing high-quality nutritional study on eye floaters, Clearer® Eye Health Supplement was created to provide targeted nutrients that support vitreous health by counteracting oxidative stress and glycation, while also combining lutein and zeaxanthin, two critical nutrients for macular health.
Our interest in the vitreous has always pointed to a larger question: what would eye care look like if we paid attention to the processes of ageing before they became diseases?
This is the direction we believe eye care needs to move in: away from waiting for vision to deteriorate before paying attention, and towards understanding how the eye changes across a lifetime and what can be done to preserve its function for as long as possible. That means better measurement, earlier identification of risk, greater attention to the connections between ocular and systemic health, and more serious discussion of the everyday factors that may influence how the eye ages.
Clearer’s mission is to contribute to that more preventative model of eye care, combining rigorous science, practical education, and long-term support so that people can protect their vision more proactively and see the world clearer .